1500% Dividend Bonanza! Pharma Stock In Spotlight After Mega Payout; Record Date Announced

Dividend Alert: Shares of Divi's Laboratories Limited will remain in focus on Monday, after the pharmaceutical major announced 1500% dividend for the financial year 2025-26. The company also reported 13% year-on-year increase in its net profit for Q4FY26.

Divi's Laboratories Dividend

The company's board of directors, on Saturday, May 23, recommended a final dividend of 1500% per equity share with a face value of Rs 2 each. The board "recommended a final dividend of ₹30/- (i.e. 1,500%) per equity share of face value ₹2/- each for the financial year 2025-26, subject to approval of the members at the ensuing 36th Annual General Meeting (AGM)." Divi's dividend payout will depend on approval at the AGM, scheduled in August.

Divi's Laboratories Dividend Record Date

To become eligible for the dividend payout, it will be necessary for investors to own the stock on or before the dividend record date. The company has fixed July 24, 2026 as the dividend record date.

Divi's Laboratories Share Price Trend

Divi's Laboratories share price closed 0.36% higher at Rs 6885 per share on BSE with a market capitalisation of Rs 1,82,775.12 crore. The stock had touched an intraday high of Rs 6,958.45 per share and an intraday low of Rs 6,790.05 per share.

The pharma stock touched its 52-week high mark of Rs 7,077.7 per share on July 8, 2025. The stock dipped to its 52-week low mark of Rs 5,637.50 per share on October 29, 2025. The pharma stock has a return on equity (ROE) of 18.47%. The stock value has surged close to 8.55% since the beginning of the year 2026. It has delivered 69% returns in two years.

Divi's Laboratories Q4 Result

Divi's Laboratories' consolidated net profit stood at Rs 751 crore in Q4FY26, up 13% from Rs 662 crore a year earlier. The firm's revenue from operations increased 10% to Rs 2,831 crore, compared with Rs 2,585 crore in Q4FY25.

The drug manufacturer also posted healthy sequential numbers. Profit after tax rose 29% from Rs 583 crore in Q3FY26, and revenue advanced 8% over the October-December FY26 quarter, when it stood at Rs 2,585 crore. The Q4FY26 profit after tax figure is attributable to shareholders of Divi's Laboratories.

Disclaimer: The views and recommendations expressed are solely those of the individual analysts or entities and do not reflect the views of Goodreturns.in or Greynium Information Technologies Private Limited (together referred as "we"). We do not guarantee, endorse or take responsibility for the accuracy, completeness or reliability of any content, nor do we provide any investment advice or solicit the purchase or sale of securities. All information is provided for informational and educational purposes only and should be independently verified from licensed financial advisors before making any investment decisions.